Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
NCT06771544Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in melanoma, sponsored by University of California, Irvine. Started Dec 2024; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06771544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771544.